NASHUA, N.H., March 28 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that the United States Patent and Trademark Office recently granted the Company U.S. Patent No. 7,333,645. This patent addresses how the Company’s CAD systems can improve cancer detection by applying technology that integrates information from multiple mammography images, including prior exams.
“We are continuously working to enhance our CAD offerings, including the development of technologies that will further improve CAD performance for radiologists,” said Ken Ferry, President and Chief Executive Officer of iCAD. “It is a strategic priority to expand our portfolio of patents that protect our intellectual property and the innovation that powers iCAD products in the detection of cancer, and we are delighted to be granted this new patent.”
This is the first patent issued to iCAD in 2008. The Company was awarded four patents in 2007 including one related to CAD for virtual colonoscopy. The Company has a total of 24 granted patents and 21 patents pending worldwide, including 16 U.S. and five European patent applications.
iCAD offers high-performance CAD solutions for both digital and film-based mammography systems. Additionally, iCAD is developing CAD solutions for use with virtual colonoscopy to improve the detection of colonic polyps. iCAD’s systems are based on sophisticated algorithms that analyze the data, automatically identifying and marking suspicious regions in the images. The result is earlier detection of hard-to-find cancers, improved workflow for radiologists and higher quality patient care.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 2,000 women’s healthcare centers worldwide. For more information, call +1 877 iCAD now or visit www.icadmed.com .
For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or
via email at ddeptula@icadmed.comicad@lhai.com
icad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
CONTACT: Darlene Deptula-Hicks, EVP and CFO of iCAD, +1-603-882-5200, ext.
7944, ddeptula@icadmed.com; Investors, Anne Marie Fields of
Lippert/Heilshorn & Associates, +1-212-838-3777, ext. 6604, icad@lhai.com;
or Public Relations, Jill Testagrossa of Schwartz Communications,
+1-781-684-0770, icad@schwartz-pr.com, both for iCAD, Inc.
Web site: http://www.icadmed.com/
